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Abstract
Prostate cancer (PCa) is the second leading form of cancer death in men. In a subset of PCa 
patients increased chemokine signaling IL-8 and IL-6 correlates with androgen therapy-resistant 
prostate cancer (CRPC). IL-8 and IL-6 are produced by prostate epithelial cells and promote PCa 
cell invasion, however the mechanisms restraining prostate epithelial cell cytokine secretion are 
poorly understood. Herein the cell-fate determinant factor DACH1 inhibited androgen therapy-
resistant prostate cancer (CRPC) tumor growth in mice. Using Dach1fl/fl/Probasin-Cre bi-
transgenic mice, we show IL-8 and IL-6 secretion was altered ~1000 fold by endogenous Dach1. 
Endogenous Dach1 is shown to serve as a key endogenous restraint to prostate epithelial cell 
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growth and restrains migration via CXCL signaling. DACH1 inhibited expression, transcription 
and secretion of the CXCL genes (IL-8, IL-6) by binding to their promoter regulatory regions in 
chromatin. DACH1 is thus a newly defined determinant of benign and malignant prostate 
epithelium cellular growth, migration and cytokine abundance in vivo.
Keywords
prostate cancer; cell fate; Dach1
INTRODUCTION
Adenocarcinoma of the prostate is the second leading cause of death in American men (1). 
Androgens increase cellular proliferation of prostatic epithelial cells via the androgen 
receptor (AR). Androgen deprivation therapy (ADT) is an important form of treatment for 
most prostate cancer patients (2). However, many tumors re-grow after 12 to 18 months (3–
6). Molecular genetic analysis in mice has confirmed clinical observation demonstrating key 
genes mediating the onset and progression of PCa, including the AR, Pten, c-Myc, and Ras. 
Although a majority of patients initially respond to ADT, most will eventually develop 
castrate resistance, defined as disease progression despite serum testosterone levels of <20 
ng/dl. The cytokine/chemokine signaling pathway is important in promoting prostate cancer 
cell proliferation and migration. The AR is believed to remain active in castrate resistant 
prostate cancer (CRPC), and several new strategies to inhibit AR signaling have recently 
been developed (7, 8).
IL-8 and IL-6 are also thought to promote prostate cancer progression (9, 10). Tumor 
derived IL-8 activates epithelial cells to promote angiogenesis and to induce recruitment of 
neutrophils. Tumor derived IL-8 activates neutrophils and tumor associated macrophages 
which release IL-6 to create a feed forward loop (10). The expression of IL-8 is increased in 
human prostate cancer correlating with poor prognosis (11, 12) and IL-8 promotes androgen 
resistance and progression of prostate cancer (13). Activation of the IL-8 receptor promotes 
EGFR signaling which in turn induces prostate cancer cellular growth (14). Increased serum 
levels of IL-6 also correlate with increased clinical stage, hormone refractory disease and 
metastasis (15, 16). IL-6 promotes conversion of prostate cancer cells to castrate resistance 
(17). In mouse models increased expression of IL-6 promotes progression of prostate cancer 
in transplantation models (18). Because IL-8 and IL-6 continue to the onset and prognosis of 
prostate cancer, and correlate with poor prognosis in some patients, it is important to 
understand the molecular mechanisms governing restraint of IL-8 and IL-6 production in the 
prostate. Prostate epithelial cells and PCa cells produce IL-8 and IL-6, however the 
mechanism normally restraining PCa epithelial cell production are poorly understand. Better 
understanding of the molecular mechanisms driving CRPC is required to define new 
therapeutic approaches.
The Drosophila dac gene is a key member of the retinal determination gene network 
(RDGN), which also includes eyes absent (eya), ey, twin of eyeless (toy), teashirt (tsh) and 
sin oculis (so), that specifics eye tissue identity (19, 20). The Dach1 gene is the mammalian 
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homologue of the Drosophila Dac gene (21), which was cloned as a dominant inhibitor of 
the hyperactive EGFR, ellipse (22, 23). DACH1 regulates expression of target genes in part 
through interacting with DNA-binding transcription factors (c-Jun, Smads, Six, ERα), and in 
part through intrinsic DNA-sequence specific binding to Forkhead binding sites (22, 24, 25, 
26). Several lines of evidence suggest DACH1 may function as a tumor suppressor. DACH1 
is phosphorylated and acetylated (27), and DACH1 acetylation mediates p53 association and 
thereby determines fine tuning of p53 signal transduction (27, 28). Patient samples have 
demonstrated reduced DACH1 expression in a variety of malignances including breast, 
prostate, non small cell lung cancer, endometrial and brain cancer (25, 26, 28, 29, 30). A 
correlation has been shown between reduced DACH1 expression and poor outcome in breast 
cancer (26), and DACH1 inhibits breast cancer tumor metastasis (31). In prostate cancer, 
DACH1 expression is reduced (25) and DACH1 was shown to bind and inhibit AR activity 
via the AR acetylation site (25, 32).
Although these studies suggest DACH1 may function as a prostate tumor suppressor several 
key questions remain unresolved, including the role of DACH1 in AR negative prostate 
cancer cells, and the function of DACH1 in prostate cancer cellular migration and invasion. 
As Dach1 gene deletion leads to a perinatal lethal phenotype, the role of endogenous Dach1 
in prostate cellular growth in vivo was unknown. DACH1 binds to the androgen response 
element (ARE) of target genes in chromatin and re-expression of DACH1 in androgen 
therapy resistant prostate cancer cell lines restored repression of AR signaling. DACH1 
abundance was rate-limiting in the recruitment of AR co-repressors (NCoR, SIRT1, HDAC3 
(33)) in the presence of the androgen antagonist, Bicalutamide (25). The finding that 
DACH1 was essential for recruitment of NCoR to endogenous AREs is considered 
important as AR transcriptional repression by AR antagonists (Bicalutamide, Finasteride) is 
dependent upon NCoR (34, 35). Furthermore, androgen antagonists function as agonists in 
the absence of NCoR (34).
Given the potential importance of DACH1 as a tumor suppressor in human prostate cancer, 
we generated prostate cancer cell lines of distinct molecular genetic makeup, including AR 
negative and AR expressing cell lines that reexpress DACH1. In order to determine the role 
of endogenous Dach1 in normal prostate cellular proliferation, we generated bi-transgenic 
mice encoding a floxed allele of the Dach1 gene and a prostate targeted Cre recombinase. 
We found DACH1 blocks prostate tumor growth and migration, inhibiting cytokine 
secretion. Transgenic Dach1 gene deletion enhanced cytokine (IL-8, IL-6) secretion ~ 1,000 
fold, defining Dach1 as a key endogenous restraint to secretion of these cytokines which 
thereby enhanced prostate epithelial cell migration. Dach1 is a key genetic determinant that 
restrains endogenous prostate epithelial cell cytokine secretion and invasion in vivo.
MATERIALS AND METHODS
Immunohistochemistry
Immunohistochemical analysis of prostate cancer cell lines was conducted using a 
polyclonal DACH1 antibody (26).
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Mice, chemicals reagents, Western blotting
Experimental procedures with transgenic mice and nude mice were approved by the 
Institutional Animal Care and Use Committee (IACUC) of Thomas Jefferson University. 
Dach1fl/fl and Probasin-Cre mice mice were in the FVB strain and were intercrossed to form 
Dach1fl/fl-Probasin-Cre bi-transgenic mice. Comparison was made between the Dach1fl/fl/
Probasin Cre and Dach1wt Probasin-Cre.
Cell culture, plasmid construction, reporter genes, expression vectors, DNA transfection, 
luciferase assays, ChIP-Seq and ChIP assays
Cell culture, DNA transfection, and luciferase assays using the CyclinA-Luc and IL-6-Luc 
and IL-8-Luc reporter genes were performed as previously described (36). Primary prostate 
epithelial cells were cultured as previously described (37). The HEK293T, PC3, the isogenic 
oncogene transformed prostate cancer cell lines (37), C4-2 and 22RV1 cells were cultured in 
DMEM supplemented with 10% fetal calf serum, 1% penicillin, and 1% streptomycin as 
previously described (26). The expression plasmids encoding an N-terminal FLAG peptide 
linked to DACH1 and DACH1 deleted of the DNA binding domain (ΔDS, aa 183-282) were 
previously described (24). Cells were plated at a density of 1 × 105 cells in a 24-well plate 
on the day prior to transfection with Superfect according to the manufacturer’s protocol 
(Qiagen, Valencia, CA). A dose-response was determined in each experiment with 50 and 
200 ng of expression vector and the promoter reporter plasmids (0.5 μg). Luciferase activity 
was normalized for transfection efficiency using β-galactosidase reporters as an internal 
control. The -fold effect of expression vector was determined with comparison to the effect 
of the empty expression vector cassette and statistical analyses were performed using a t-
test. ChIP-Seq (Chromatin Immunoprecipitation Sequencing) was previously conducted (31) 
using an anti-FLAG antibody to the N-terminal Tag of the DACH1-FLAG expression fusion 
protein (24, 27, 31, 38). The prior data was interrogated for significant DACH1 association 
in chromatin using genes identified as candidate targets of DACH1 in the current studies. 
MDA-MB-231 cells stably expressing FLAG-tagged DACH1 were used for analysis with 
comparison made to MDA-MB-231 cells stably expressing vector alone. Briefly, 
approximately 107 cells were fixed with 1% formaldehyde for 10 min at room temperature. 
The chromatin template was fragmented to 200 to 500 bp with sonication. The quality-
filtered 25-nt short sequence reads were aligned to the hg18 (NCBI Build 36) human 
genome sequence using ELAND software, allowing up to two mismatches with the genome 
sequence. We obtained approximately 5.9 million uniquely aligned short sequence reads 
each for DACH1-p901 and IgG control samples in breast cancer cells. As the 25-nt short 
sequence reads originate from the ends of approximately 300 bp ChIP fragments, we shifted 
the locations of short reads toward the center of ChIP fragments by 150 nt (sense and 
antisense strand reads are shifted in opposite directions) and counted the resulting reads in 
400 bp nonoverlapping consecutive windows along the human genome. As the total number 
of uniquely aligned reads in the two samples (DACH1-p901 and IgG) is very similar, it was 
meaningful to directly compare window read counts of the two samples and look for 
DACH1 enriched regions. Model-based Analysis for ChIP-Seq (MACS) software was used 
to identify putative DACH1 binding sites in the DACH1 IP using IgG as control. Peaks were 
reported using a raw p-value cutoff of 0.01 (Default is 1e-5). Default settings were used for 
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all other parameters. The peak intervals identified for IL-6, IL-8, Cyclin A2 and Cyclin E1 
were within this set, however based on the MACS peak call the binding was weak. We 
therefore initiated ChIP experiments to verify Dach1 association with these genes of interest. 
The primers used for the IL-6 and KC (mouse homologue of IL-8) were previously 
described (39).
Cell Proliferation Assays
Cells infected with MSCV-IRES-GFP, MSCV-DACH1-IRES-GFP, or MSCV-DACH1ΔDS, 
were seeded into 96 well plates in normal growth medium, and cell growth was measured 
daily by MTT assays using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide.
Colony forming assays
4 × 103 cells were plated in triplicate in 3 ml of 0.3% agarose (sea plaque) in complete 
growth medium in the presence or absence of 2 μg/ml doxycycline overlaid on a 0.5% 
agarose base, also in complete growth medium. 2 weeks after incubation, colonies more than 
50 μm in diameter were counted using an Omnicon 3600 image analysis system. The 
colonies were visualized after staining with 0.04% crystal violet in methanol for 1 to 2 h.
Tumor xenografts
22Rv1 cells stably transduced with expression vectors encoding DACH1, DACH1 ΔDS or 
empty vector cassette were implanted by subcutaneous injection into the flank of 6- to 8- 
week old nude mice. Comparisons were made between groups with 7 mice in each group. 
The tumor volume was calculated using the equation  where “a” and “b” are tumor 
length and width respectively. At the completion of the experiments, tumors were excised, 
weighed and statistical significance of differences in tumor volume was analyzed using a 
linear mixed model.
Immunohistochemistry (IHC) staining
Paraffin-embedded tissue blocks were used for IHC in the Sidney Kimmel Cancer Center 
Pathology Core Facility as previously described (40). The antibody to Dach1 (10914-1-AP, 
Proteintech), Ki67 (RM-9106-S1, Thermo) and TUNEL (TACS2 TdT DAB, Trevigen) was 
previously described (28).
Cell Cycle Analysis
Cell cycle parameters were determined using laser scanning cytometry. Cells were 
processed by standard methods using propidium iodide staining of cell DNA. Each sample 
was analyzed by flow cytometry with a FACScan Flow Cytometer (Becton-Dickinson 
Biosciences, Mansfield, MA) using a 488 nm laser. Histograms were analyzed for cell cycle 
compartments using ModFit version 2.0 (Verity Software House, Topsham, ME). A 
minimum of 20,000 events were collected to maximize statistical validity of the 
compartmental analysis. Apoptosis was determined by Annexin V staining (41).
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Western Blot
Western blot assays were performed in cells as indicated. Cells were pelleted and lysed in 
buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 
0.1% Tween 20) supplemented with a protease inhibitor cocktail (Roche Diagnostics, 
Mannheim, Germany).
Microarray and Cluster Analysis
DNA-free total RNA isolated from DACH1 expressing PC3 stable lines were used to probe 
human OneArray (Phalanx). RNA quality was determined by gel electrophoresis. Analysis 
of the arrays was performed using GeneSpring. Arrays were normalized using robust multi-
array analysis, and the p value of 0.05 was applied as a statistical criterion for differentially 
expressed genes. These genes were then grouped using hierarchical clustering with 
“complete” agglomeration, and each cluster was further analyzed based upon the known 
function of the genes contained in the cluster. Expression profiles are displayed using 
Treeview. Classification and clustering for pathway level analysis were performed by using 
gene sets ASSESS (Analysis of Sample Set Enrichment Scores), and DAVID. ASSESS 
provides a measure of enrichment of each gene set in each sample.
Transwell Migration, 3D matrigel invasion and migratory velocity assays
In wound healing assays, cells were grown to confluence on 12-well plates (42). Transwell 
migration assays were conducted as previously described (43). The assessment of migratory 
velocity and distance was conducted using time-lapse video images that were collected and 
stored as images using Metamorph, version 3.5, software as previously described (44).
Cytokine Array Analysis
Human cytokine arrays spotted on nitrocellulose membranes were obtained from Raybiotech 
(Norcross, GA) (45). Conditioned medium was prepared from cells transduced with an 
expression vector encoding DACH1 or DACH1 ΔDS by culturing cells in serum free 
DMEM for 24–48 hrs. The conditioned medium from Dach1+/+ and Dach−/− PEC was 
prepared from cells grown in serum free media for 24 hrs.
Assessment of CXCL abundance
To quantitate CXCL expression, real time PCR analysis was conducted using equal amounts 
of purified RNA samples which were reverse transcribed using the Iscript Reverse 
transcriptase kit (Bio-Rad, Hercules, CA) to form cDNA, which was subjected to SYBR 
Green based Real-Time PCR relative quantification method for amplification of IL-6 and 
IL-8 transcripts (43). The abundance of secreted IL-6, human IL-8, murine KC was 
determined by ELISA (Raybiotech, Nacross, GA).
Coexpression analysis in GSE21034
A normalized mRNA expression dataset for Prostate Adenocarcinoma (46) was downloaded 
from the cBioPortal for cancer genomics and used to evaluate coexpression of IL6, IL8, and 
DACH1 transcript levels (46, 47). This dataset includes mRNA profiles for 131 primary 
tumor, 29 matched normal prostate, and 19 metastasis samples. Pearson’s correlation 
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coefficient was calculated for these transcripts for all samples and within normal prostate 
and prostate cancer, and metastatic sample groups. The 29 matched tumor-normal pairs were 
used to investigate changes in mRNA expression for IL6 and IL8 versus DACH1 in tumor 
relative to normal baseline. Samples were divided into a subset showing a trend in prostate 
cancer samples vs normal adjacent prostate tissue for a decrease in DACH1 accompanied by 
an increase in IL6 or IL8, and a subset of other samples in order to illustrate the frequency of 
this relationship between IL6/IL8 and DACH1.
RESULTS
DACH1 inhibits CRPC contact-independent growth
In order to determine whether DACH1 was capable of inhibiting AR negative prostatic 
cancer cell contact-independent growth, the PC3 cell line was stably transduced with an 
expression vector encoding DACH1. In order to define the genetic cell-cycle targets of 
DACH1, microarray analysis was conducted of the cell lines (Fig. 1A). Interrogation of the 
cell cycle control proteins demonstrated that, unlike several other cell types in which cyclin 
D1 is a direct-target of DACH1 repression, the cyclin A1, cyclin E1, cyclin E2, and cyclin A2 
genes were repressed in PC3 cells (Fig. 1A, highlighted in red text). The mRNA data for all 
experiments shown by color display in Figure. 1A is shown quantitatively for PC3 cells in 
Supplemental Fig. 1A. We examined the possibility that the cyclin E1 gene was a direct 
transcriptional target of DACH1. The cyclin E1 promoter linked to a luciferase reporter gene 
was examined for responsiveness to DACH1. The DS domain (dac and ski/sno domain) (21) 
is required for transcriptional regulation and binding to gene targets in the context of local 
chromatin (24). Transfection of a DACH1 expression vector with the cyclin E1 promoter-
reporter in PC3 cells induced a dose-dependent repression which was contingent upon the 
DS domain (Supplemental Fig. 1B). Antibodies directed to the mutant of DACH1 (ΔDS) 
domain or the DACH1 protein demonstrated the presence of DACH1 in PC3 cells stably 
expressing DACH1 or the ΔDS domain (Fig. 1B). Western blot directed to the N-terminal 
FLAG epitope demonstrate similar levels of exogenous DACH1 Wt or DACH1 ΔDS 
domain protein. Stable DACH1 expression reduced PC3 cell proliferation by approximately 
50%, assessed by both the MTT assay and cell counting (Fig. 1C, D). PC3 cell growth, 
assayed by colony number in soft agar, was also inhibited approximately 80% by DACH1 
(Fig. 1E). Inhibition of colony number by DACH1 was abrogated by deletion of the DS 
domain (Fig. 1F, G).
The C4-2 prostate cancer cells are a well characterized model of androgen-independent 
prostate cancer. The PI3-Kinase/Akt pathway is constitutively active in C4-2 due to the loss 
of the tumor suppressor phosphatase and tensin homolog (PTEN), which is also deleted or 
inactivated in up to 70% of advanced androgen-independent prostate cancers (48). DACH1 
or the DACH1 ΔDS domain mutant was expressed in the C4-2 cells (Fig. 1H), as evidenced 
by immunohistochemistry to the DACH1 protein. Western blot to the N-terminal tag of 
DACH1 demonstrated similar levels of the exogenous DACH1 or DACH1 ΔDS proteins 
(Fig. 1H). Expression of DACH1 reduced C4-2 cellular proliferation as assessed by the 
MTT assay and cell counting (Fig. 1I, J). DACH1 reduced proliferation ~50% at 6 days.
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DACH1 inhibits CRPC and PEC growth in vivo
In order to determine whether DACH1 inhibited CRPC tumor growth in vivo, tumor size of 
DACH1 transduced PC3 cells was determined weekly after implantation (Fig. 2A). The 
tumor size increased in the vector control, but was reduced by the expression of DACH1 
with an approximately 50% decrease in tumor volume at week 7. Deletion of the DS domain 
abrogated the reduction of tumor growth in nude mice. The tumor weight was similarly 
reduced, approximately 50% in vivo (Fig. 2B), whereas deletion of the DS domain abrogated 
the inhibition of tumor weight. The CWR22Rv1 line was derived from a relapsed human 
prostate cancer CWR22 xenograft (49). This line encodes a ligand independent AR variant 
that arises by splicing of cryptic exons (50). The CWR22Rv1 cells express the AR variant 
and are p53 positive, unlike PC3 cells, which are AR negative and p53 negative. Re-
expression of DACH1 in CWR22Rv1 cells also reduced tumor growth in mice 
approximately 50% at 5 weeks post implantation (Fig. 2C). Deletion of the DACH1 DS 
domain reduced, but did not abrogate the inhibition of cell growth, suggesting 
distinguishable domains of DACH1 may be involved in the inhibition of cellular growth in 
AR negative vs. AR positive cells in vivo. The weight of the tumor was reduced >80% by 
DACH1 expression (Fig. 2D).
In order to determine whether the expression of DACH1 was reduced upon oncogenic 
transformation of prostate epithelial cells (PEC), we determined the abundance of DACH1 
in isogenic oncogene-transduced PEC (37) (Fig. 2E). Western blot analysis demonstrated a 
reduction in DACH1 abundance in PEC transduced with distinct oncogenes (c-Myc, NeuT, 
Ha-Ras, v-Src) when normalized to the protein loading control vinculin (Fig. 2F). 
Multiplicate analysis of the DACH1 mRNA abundance by quantitative PCR analysis 
demonstrated reduced DACH1 mRNA levels in each of the oncogene transduced lines 
(Supplemental Fig. 1C)
The isogenic murine PCa lines were introduced into FVB mice, and after 6 weeks the 
extirpated tumors examined for DACH1 abundance with comparison made to benign murine 
PEC. Compared with the normal murine PEC, from which the isogenic oncogene 
transformed lines were derived, DACH1 abundance was significantly reduced (Fig. 2G). In 
order to determine whether the cell cycle target genes identified as DACH1 targets in 
cultured PC3 cells were altered in abundance in the isogenic oncogene transformed cells, 
microarray analysis was conducted. In both tissue culture and in extirpated tumors grown in 
vivo, the expression of cyclin E1 and cyclin A2 was increased (Fig. 2H, I). In contrast, the 
mRNA levels of several other cyclins (cyclin D2, cyclin D3, cyclin A1, and cyclin B3) was 
unchanged (Fig. 2H, I). Cyclin D1 mRNA levels were induced in the NeuT and Src isogenic 
lines in tissue culture and in all lines in vivo (Fig. 2H, I). The mRNA data for all 
experiments shown by color display is shown quantitatively for in vitro tissue culture and in 
vivo tumors (Supplemental Fig. 1D–E).
Conditional Dach1 gene knockout in the prostate demonstrates a role for endogenous 
Dach1 as an inhibitor of cellular proliferation and an inducer of apoptosis
In order to determine the potential role for Dach1 in prostatic cellular proliferation in vivo, 
bi-transgenic mice were generated (Supplemental Fig. 2A). The Dach1fl/fl mice were 
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intercrossed with Probasin-Cre mice, in which Cre recombinase is expressed in the basal and 
luminal epithelial cells of the prostate. Immunohistochemical staining demonstrated the loss 
of Dach1 in both the anterior and ventral prostates of the bi-transgenic mice (Supplemental 
Fig. 2B–E). An analysis of cellular proliferation and apoptosis was conducted. Ki67 
staining, a surrogate measure for cellular proliferation, was significantly increased in the 
PEC of the Dach1fl/fl/Probasin-Cre mice (Fig. 2J, Supplemental Fig. 3A, B). TUNEL 
staining was conducted to assess the effect of endogenous Dach1 on cellular survival in 
vivo. The percentage of apoptotic cells was reduced ~3-fold in the Dach1−/− prostate (Fig. 
2K, Supplemental Fig. 3C, D). Consistent with the finding that DACH1 inhibited cyclin A1, 
A2 and cyclin E1 in the prostate cancer cell lines, immunohistochemical staining 
demonstrated that the abundance of cyclin A2 and cyclin E1 was increased in the Dach1−/− 
PEC (Fig. 2L, M, Supplemental Fig. 3E, F), as was the abundance of cyclin D1 and cyclin 
A1 (Supplemental Fig. 4).
DACH1 inhibits prostate cancer cellular migration and persistence of migratory 
directionality
In order to determine whether DACH1-regulated prostate cancer cellular migration, the 
effect of DACH1 on the ability of PC3 cells to traverse a membrane was assessed. DACH1 
expression in PC3 cells reduced transwell migration by >90% (Fig. 3A, B) and deletion of 
the DACH1 DS domain abrogated the effect on cell migration (Fig. 3B). In order to define 
further the distinct components of cell migration regulated by DACH1 expression, video 
microscopy was conducted to determine the distance and effect of DACH1 on prostate 
cancer cellular migratory directionality. DACH1 inhibited the distance traveled by PC3 
cells. The effect was abrogated by the deletion of the DS domain (Fig. 3C). The velocity of 
migration was also reduced by DACH1, requiring the DACH1 DS domain (Fig. 3D).
In order to define the mechanisms by which DACH1 inhibited cellular migration, 
microarray analysis was conducted. Interrogation of the microarray analysis was conducted 
to determine functional pathways using KEGG and GO. The enrichment score for each 
pathway, the name of the pathway and the number of genes within each GO-defined 
functional pathway was determined and represented graphically for each parameter as a 
unique dimension in Fig. 3E. The cytokine/cytokine receptor interaction pathway was highly 
enriched. We therefore examined the cytokine/chemokine signaling pathway as it is known 
to promote cellular proliferation and migration. A module of cytokine signaling was 
selectively repressed by DACH1, including IL-6, IL-8 and CXCL6, 1, 2, 5 (Fig. 3F). 
Deletion of the DS domain abrogated DACH1-mediated repression of IL-8 and IL-6 
expression (Fig. 3F). The mRNA data for all experiments in PC3 cells shown by color 
display is also shown quantitatively in Supplemental Figure. 5A.
In order to determine whether DACH1-mediated repression of IL-8 was oncogene specific, 
we assessed the isogenic oncogene transformed prostate cancer cell lines, in which DACH1 
expression was reduced (Fig. 4A). Microarray analysis shown colorimetrically of the 
isogenic prostate cancer cell lines in tissue culture (Fig. 4A), or in vivo in tumors derived 
from FVB mice (Fig. 4B), demonstrated increased expression of IL-6 in the Ha-Ras 
transformed line and increased IL-8 (CXCL1) in each of the lines transformed by distinct 
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oncogenes (c-Myc, NeuT, Ha-Ras, V-Src). IL-6 and IL-8 mRNA was increased in each of 
the cell lines when grown as tumors in mice. Similar data is shown quantitatively in 
Supplemental Fig. 5B, C. Immunohistochemical staining of the extirpated tumors 
demonstrated a significant inverse correlation between DACH1 and the abundance of 
CXCL1 (KC), IL-6 and CXCR2 (the receptor for CXCL1) (Fig. 4C–E).
In order to determine whether a clinical correlate existed for DACH1-mediated repression of 
cellular migration, we hypothesized that DACH1 expression may be lost in metastatic 
prostate cancer. Interrogation of clinical databases demonstrated the relative abundance of 
DACH1 was reduced in prostate cancer compared with benign prostate disease, with 
significant further reduction in metastatic prostate cancer samples (Fig. 4F). We next 
examined the prostate cancer sample and the adjacent normal prostate tissue of individual 
patient samples. Individual patient samples of patients matched showed a decrease in Dach1 
levels associated with an increase in IL-6 and IL-8 mRNA level in the prostate tumor 
compared with adjacent normal prostate tissue. This decrease in DACH1 (DACH1 
expression) correlated significantly with an increase in IL-6 and IL-8 (Fig. 4G, H, t test, 
p<0.05). The mRNA level in individual patient matched samples is shown in Supplemental 
Fig. 6A.
In order to determine the mechanisms by which DACH1 reduced the cytokine signaling 
module, we considered the possibility that DACH1 may inhibit the transcription of CXCL 
genes. We examined the IL-6 and IL-8 promoters. Both IL-6 and IL-8 were repressed in a 
dose-dependent manner by DACH1, and repression required the DS domain (Fig. 4I, J). 
Western blot analysis of the transfected PC3 cells using a FLAG antibody directed to the N-
terminal of DACH1 protein demonstrated a dose-dependent increase in the abundance of 
transfected wild type or mutant DACH1 protein when normalized to vinculin protein as a 
loading control (Fig. 4K).
In order to determine at a higher level of resolution the mechanism by which DACH1 
repressed IL-6 and IL-8 mRNA and promoter activity, we determined whether DACH1 was 
recruited in the context of chromatin to the promoters of regulatory regions of these genes. 
Genome wide chromatin immunoprecipitation (ChIP-Seq) analysis previously conducted in 
MDA-MB-231 cells expressing FLAG-Tagged DACH1 (24, 27), identified enrichment of 
Tag density for DACH1 at the cell cycle DACH1-regulated target genes (cyclin E1, cyclin 
A2, cyclin A1) and the cytokine target genes IL-6 and IL-8 (Supplemental Fig. 6B). The 
ChIP analysis of the cyclin E1, cyclin A2, IL-6 and IL-8 promoter (in 293T cells) using 
oligonucleotide primer targeted to the AP-1 regulatory region demonstrated recruitment of 
DACH1, but not DACH1 ΔDS, to the cyclin E1, cyclin A2, IL-6 and IL-8 promoters at the 
AP-1 sties (Fig. 4L, Supplemental Fig. 6C–D).
Dach1 inhibition of cellular migration involves secreted cytokines (IL-6, CXCL1)
In order to determine whether endogenous DACH1 regulated the secretion of the cytokine 
signaling mRNA module identified in human prostate cancer cells in tissue culture, the 
prostatic epithelium of the bi-transgenic mice (Dach1fl/fl/probasin Cre) was analyzed. A 
cytokine array analysis demonstrated increased secretion of CXCL signaling in the 
Dach1fl/fl/Probasin-Cre bi-transgenic mice prostatic epithelial cells (PEC) in culture 
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(Supplemental Fig. 7A–D). The increased abundance of IL-6 and KC (homologue of human 
IL-8) in Dach1−/− PEC was confirmed by quantitative ELISA (Fig. 5A, B, Supplemental 
Fig. 8A, B). The abundance of IL-6 was increased ~1,000 -fold (Fig. 5A, Supplemental Fig. 
8A) and the abundance of KC was also increased ~1,000 fold (Fig. 5B, Supplemental Fig. 
8B) when assayed by ELISA. The Dach1−/− PEC derived from the anterior prostate showed 
a similar increase in cellular migatory distance and velocity (Supplemental Fig. 8C–D). The 
mRNA levels for IL-6 and IL-8 determined by QT-PCR were increased ~6–fold in 
Dach1−/− vs Dach1+/+ PEC (Supplemental Fig. 9A, B). The circulating serum levels for 
IL-6 and IL-8 determined by quantitative ELISA in the Dach1 wild-type vs. knockout mice 
show a 3-fold difference in abundance (Fig. 5D, E).
The Dach1−/− PEC of the ventral prostate showed a ~250% increase in both cellular 
migratory distance (data not shown) and velocity (Fig. 5C, Supplemental Fig. 10A). The 
addition of media from the Dach1−/− PEC enhanced migration of Dach1+/+ PEC (Fig. 5C 
lanes 1 vs. 2) and media from Dach1+/+ PEC reduced migration of Dach1−/− PEC (Fig. 5C 
lanes 9 vs. 10). This finding suggested that endogenous Dach1 inhibits the secretion of 
factors that promote PEC cellular migration (Fig. 5F). The addition of IL-6 or CXCLI (KC, 
murine homologue of IL-8) enhanced migration of Dach1+/+ PEC. Addition of an 
immunoneutralizing antibody to IL-6 or CXCLI reduced the migration of Dach1+/+ PEC 
(Fig. 5C, Supplemental Fig. 10A).
We considered potential mechanisms contributing to the reduction in DACH1 abundance in 
prostate cancer cell lines. DNA methylation of gene regulation may contribute to reduced 
expression. Treatment of the PC3 cell line with the DNA methyltransferase inhibitor 5-
azacytidine, demonstrated a substantial induction of DACH1 abundance by Western blot 
(Supplemental Fig. 11), suggesting that DNA methylation may contribute to the reduction of 
DACH1 abundance in prostate cancer cell lines.
In order to determine whether the inverse relationship between DACH1 and IL-8/IL-6 
expression was found in human prostate cancer we examined a data base in which matched 
prostate cancer and adjacent normal tissue had been interrogated by microarray gene 
expression (Supplemental Fig. 12A, B). The data showed substantial variation in gene 
expression between patient samples but an overall trend for reduced DACH1 mRNA and 
increased IL-8 and IL-6 mRNA in the tumor compared with adjacent normal tissue. 
Although matched data for progression of primary to metastatic samples was not available, a 
similar trend was observed comparing metastatic prostate cancer lesions with non-
transformed adjacent prostate tissue (Supplemental Fig. 12A, B).
DISCUSSION
Using bi-transgenic mice, the current studies demonstrate for the first time that the 
endogenous cell fate determination factor pathway defined by Dach1 restrains prostate 
epithelial cell proliferation, migration and cytokine secretion. IL-8 and IL-6 are known to 
promote prostate cancer progression (51, 52, 53) however the mechanisms governing the 
restraint of IL-8 and IL-6 mRNA expression in the prostate were previously unknown. 
Herein, Dach1 genetic deletion increased IL-6 and KC abundance ~1000-fold, illustrating 
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Dach1 is a key endogenous determinant of IL-8 and IL-6 production. Oncomine analysis of 
mRNA abundance for IL-6 and IL-8 demonstrated increased expression in metastatic PCa, 
compared with normal prostate in some (Fig. 4F), but not in all clinical data sets 
(Supplemental Fig. 12) likely due to the heterogeneous nature of prostate cancer as shown in 
the wide spread of individual patient data (Supplemental Fig. 12). The loss of DACH1 
expression in metastatic prostate cancer suggests that DACH1 may serve as a clinically 
relevant prostatic cancer metastasis suppressor in a subset of prostate cancers.
In two separate prostate cancer models of castrate resistant prostate cancer, we demonstrated 
DACH1 blocks prostate tumor growth in vivo. DACH1 inhibited prostate cancer cell growth 
in immune competent mice in four murine prostate cancer cell lines transformed by distinct 
oncogenes (Ha-Ras, c-Myc, v-Src, NeuT). The isogenic prostate cancer cell lines resemble 
prostate adenocarcinoma cancer by histology, by gene expression and by genomic 
rearrangements (37). DACH1 mRNA and protein levels were reduced in the isogenic 
prostate cancer cell lines and re-expression of DACH1 reduced tumor growth in immune-
competent mice. These studies extend the prior findings in mice that showed PTEN and 
p27Kip1 restrain prostate epithelial cell proliferation in vivo (54). The current studies also 
extend prior observations that DACH1 represses AR expression in PCa Cells (25). Herein, 
the PC3, CWR22Rv1 and C4-2 cell lines were each repressed by DACH1 expression. The 
genetic make up of these cell lines involves distinct mutations. PC3 cells are AR negative, 
p53 negative, PTEN negative and p38 negative (55) indicating the inhibition of cell 
proliferation by DACH1 is p53-independent. The CWR22Rv1 cells are AR positive and p53 
positive, but are PTEN positive, indicating DACH1 inhibition of PCa doesn’t require PTEN 
inactivation. In the AR mutant LNCaP cells, DACH1 inhibited prostatic cancer cellular 
DNA synthesis and growth in colony forming assays and blocked contact-independent 
growth in soft agar. Together, these studies demonstrate that DACH1 has anti-proliferative 
functions in both AR-positive, AR-negative and AR mutant prostate cancer cell lines.
The current studies demonstrate DACH1 inhibits human and murine prostate tumor growth 
in vivo. The inhibition of AR negative PC3 cells, proliferation and colony formation, 
required the DS domain of DACH1. The repression of cyclin A1 also required the DS 
domain. DACH1 repressed cyclin E1 and cyclin A1 in PC3 cells, whereas cyclin E1 and 
cyclin A2 were repressed in each of the isogenic prostate cancer lines. In LNCaP cells, the 
cell-cycle signaling module repressed by DACH1 was not determined (25), however, 
induction of DACH1 expression in LNCaP cells repressed cyclin D1 abundance (data not 
shown). Together these findings suggest DACH1 targets distinct components of the cell-
cycle to reduce cell proliferation in different cell lines. DACH1 conveys transcriptional 
repression directly via DNA binding to FKHR sites (24), indirectly through association with 
other transcription factors (c-Jun, So/SIX, AR), or through binding the co-regulator protein 
CA150 (54). The mechanism by which DACH1 inhibited AR-ve prostate cancer cell growth 
correlated with repression of cyclin E1 and DACH1 bound cyclin E1, cyclin A1 and cyclin 
A2 promoters in ChIP assays, consistent with a direct repression mechanism.
Using Dach1fl/fl/Probasin-Cre prostate epithelial cells, we demonstrated that endogenous 
Dach1 restrains a homotypic pro-migratory signal in the murine prostate epithelium via 
repression of IL-6 and IL-8. Deletion of endogenous Dach1 reduced IL-6 and IL-8 protein 
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abundance ~1000-fold. The normal mechanisms governing prostate epithelial cell 
production of IL-6 and IL-8 is important because these cytokines have profound effects on 
prostate cancer onset and progression. DACH1 inhibited PCa cellular migration across a 
membrane and inhibited migratory distance and velocity via homotypic secretion of 
cytokines. Pathway analysis of microarray gene expression profiling from tumor xenografts, 
demonstrated DACH1 repressed a cytokine module including IL-6 and IL-8 (KC). 
Immunoneutralizing antibodies demonstrated the importance of DACH1-mediated inhibition 
of IL-6 and IL-8 in determining prostate cancer cellular migration directionality. DACH1 
repressed transcription of the IL-6 and IL-8 promoters and DACH1 was associated in the 
local chromatin by ChIP at the IL-6 and IL-8 promoters. DACH1 reduced IL-6 and IL-8 
mRNA abundance ~6-fold, indicating DACH1 governs both transcriptional and non-
transcriptional mechanisms. Given the importance of IL-8 and IL-6 in human prostate 
cancer progression, the current studies are important in identifying a key endogenous 
restraint of cytokine production that is lost during prostate cancer development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DACH1 inhibits AR-negative prostate cancer cell proliferation and contact 
independent growth by the DS domain
A) Treeview display of microarray gene expression studies conducted on PC3 cells stably 
expressing either vector control or DACH1. The cell cycle control proteins are shown with 
the relative abundance, demonstrated with a color scale as shown. DACH1 inhibits cyclin 
E1, E2, A1, A2 expression. B) Phase contrast using immunofluorescent microscopy for PC3 
stable cell lines for DACH1 and DAPI as a nuclear stain. Western blot of PC3 stable cell 
line with antibody to the N-terminal FLAG tag of DACH1. C) The cellular proliferation rate 
determined by MTT assay or D) cell counting. E) Colony forming assays were conducted 
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with PC3 stable cell lines expressing control vector, DACH1 or ΔDS with colonies stained 
using crystal violet and F) colony number or G) colony size determined using N>5 separate 
experiments. H) C4-2 cells expressing either control vector DACH1 or the DACH1 ΔDS 
mutant were assessed for DACH1 abundance by immuno-histochemistry. DAPI and 
immunofluorescence for DACH1 is shown. Western blot is shown of the cells with an 
antibody directed to the N-terminal FLAG tag. I) The cellular proliferation rate of C4-2 cells 
expressing DACH1 or mutant DS was determined by either MTT assay or J) cell counting. 
Data are mean ±SEM for N>5 throughout.
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Figure 2. DACH1 inhibits prostate cancer tumor growth and cellular proliferation in mice
A–B) PC3 cells stably transduced with either control vector DACH1 or the DACH1 ΔDS 
mutant were introduced into nude mice and assessed by A) tumor size or B) tumor weight 
after implantation C–D) 22RV1 cells stably expressing either DACH1, DACH1 ΔDS or 
vector control were assessed after implantation into mice by C) the tumor size or D) the 
tumor weight. The data are shown as mean ±SEM for N>7 throughout. E–F) Dach1 
expression is detected by Western blot in primary mouse (FVB) PEC and isogenic oncogene 
transformed cell lines derived from FVB PEC. H) Microarray gene expression of FVB PEC 
or isogenic oncogene transformed PEC with relative abundance of cyclins shown. G) PEC 
line tumor grown in mice and primary prostate gland from which lines were derived, were 
immunostained for Dach1 and the % of Dach1 positive cells determined. H) Microarray 
analysis of cyclin gene expression in isogenic PEC grown in tissue culture or I) grown as 
tumors and then extirpated from FVB mice. The changes in gene expression are shown 
calorimetrically. Gene names are shown to the right of the panels. Genes highlighted in red 
are induced in both tissue culture and in vivo and were followed for mechanistic analysis. J) 
Analysis of bi-transgenic mice encoding Dach1fl/fl/Probasin-Cre by immunohistochemical 
staining for Ki67 in the ventral prostate shown at 10x and 40x. Data is shown for mean 
±SEM N>100 cells. K) Apoptosis determined by TUNEL staining of the ventral prostate. 
Data shown as mean ±SEM N>100 cells. L) Immunohistochemical staining for cyclin E1 
and M) cyclin A2 in the ventral prostate of bi-transgenic mice encoding Dach1fl/fl/Probasin-
Chen et al. Page 19
Cancer Res. Author manuscript; available in PMC 2016 May 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Cre mice. Transgenic deletion of Dach1 in the prostate epithelial cells enhances cellular 
proliferation and reduces cellular apoptosis.
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Figure 3. DACH1 inhibits transwell migration and cytokine gene expression via the DS domain
A) PC3 cells stably expressing either vector, DACH1 or ΔDS were stained after transwell 
migration. B) The relative migration is shown for N>5 separate experiments. C) The PC3 
stable cell lines were analyzed by video microscopy for distance traveled. Representative 
examples of individual cell tracking are shown for stable PC3 cells co-incubated with the 
media from cells expressing either DACH1, or DACH1 ΔDS. D) The cellular migratory 
velocity for the PC3 cells is shown as mean ±SEM for three separate experiments. E) 
Microarray analysis of PC3 cells stably expressing either DACH1, DACH1 ΔDS or vector 
control were analyzed for functional pathways using KEGG. The GO terms, the enrichment 
score, and number of gene enhanced for each GO term are shown. F) The relative abundance 
of genes significantly altered by DACH1 via the DS domain in the cytokine-cytokine 
receptor interaction categories is shown. DACH1 inhibits CXCL gene expression as shown 
by the blue color indicating repression in the presence of DACH1 expression. Genes 
highlighted in red are repressed by DACH1 expression via the DACH1 DS domain and used 
for further analysis.
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Figure 4. Dach1 expression is reduced in oncogenic transformed PEC and inversely co-related 
with cytokine production
A) Microarray based gene expression of cytokines/chemokines in isogenic PEC in tissue 
culture or B) from tumors grown in FVB mice. The relative expression levels from the 
tumors in vivo are shown in C-E. F) Relative DACH1 mRNA levels were determined from 
Oncomine in either prostate cancer samples or benign prostate disease. DACH1 levels are 
significantly reduced in metastatic prostate cancer samples. G–H) mRNA abundance for 
DACH1 and either IL-6 or IL-8 in adjacent normal prostate tissue vs prostate cancer 
samples for individual patients was determined. The relative changes in expression for 
normal adjacent prostate tissue vs cancer is shown. Samples with a decrease in DACH1 
mRNA abundance and increase in IL-6 or (H) IL-8 abundance are shown in the left upper 
quadrant. This quadrant expressing a decrease in DACH1 mRNA and corresponding 
increase in mRNA levels in individual patient cancer samples vs adjacent normal prostate 
epithelium was significantly enriched. I) The relative luciferase reporter activity of the IL-6 
and J) IL-8 promoter was normalized to 1 for the vector control. The luciferase promoter 
reporters were transfected into PC3 cells, together with equimolar amounts of either vector, 
DACH1 expression vector or the ΔDS expression vector. Data are mean ± SEM for N>5 
separate experiments. K) Western blot of transfected PC3 cells showing relative abundance 
of the exogenous DACH1 assessed by FLAG epitope. Vinculin is shown as a protein 
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loading control. L) ChIP of the IL-6 and IL-8 promoter with oligonucleotide primers 
directed to the regulatory region of the genes as shown.
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Figure 5. Dach1 is a dominant endogenous restraint of prostate epithelial cell cytokine 
production and thereby cellular migration
The Dach1fl/fl Probasin-Cre prostate epithelial cells were cultured and comparison was made 
to Dach1+/+. A) ELISA was used to determine the relative abundance of cytokines in the 
supernatant (ventral prostate epithelial cells) in culture for IL-6 and B) KC in pg/mL (Note: 
Log scale). C) Analysis of migratory cell velocity for prostate epithelial cells derived from 
Dach1+/+ or Dach1−/− PECs. Cells were co-incubated with media derived from either 
Dach1+/+ or Dach1−/−, incubated with IL-6 or anti-IL-6 antibody. KC or anti-KC antibody 
is indicated in the Figure. P value is indicated (significance <0.05). Data is shown as mean ± 
SEM of three separate experiments. D) ELISA was used to determine the relative abundance 
for cytokines in the Dach1 wild-type vs. knockout mice in circulating serum of IL-6 and E) 
KC in pg/mL (Note: Log scale). F) Schematic representation of Dach1 as key determinant of 
prostate cellular cytokine secretion and cellular proliferation.
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